Research Analysts Offer Predictions for ANIX Q1 Earnings

Anixa Biosciences, Inc. (NASDAQ:ANIX) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Anixa Biosciences in a research note issued on Tuesday, March 25th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($0.10) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10).

Other equities analysts have also recently issued reports about the company. Maxim Group assumed coverage on Anixa Biosciences in a research note on Friday, March 21st. They set a “buy” rating and a $10.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday.

Anixa Biosciences Stock Performance

Anixa Biosciences stock opened at $3.08 on Wednesday. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The stock’s 50 day moving average price is $2.96 and its 200 day moving average price is $3.01. The firm has a market capitalization of $99.17 million, a PE ratio of -7.90 and a beta of 0.86.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in ANIX. Virtu Financial LLC acquired a new stake in Anixa Biosciences in the 3rd quarter valued at approximately $34,000. Westside Investment Management Inc. grew its stake in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares in the last quarter. Prosperity Wealth Management Inc. bought a new position in shares of Anixa Biosciences in the fourth quarter worth $54,000. Millennium Management LLC acquired a new position in shares of Anixa Biosciences during the fourth quarter valued at $26,000. Finally, Jane Street Group LLC acquired a new stake in Anixa Biosciences in the fourth quarter worth about $67,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar acquired 43,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the purchase, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 75,289 shares of company stock worth $177,021 over the last 90 days. Insiders own 25.30% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.